Experimental Ebola Treatment Trial Starts in DRC Amid Largest Outbreak
A clinical trial of experimental Ebola treatments began in the Democratic Republic of Congo, enrolling its first patient on Thursday as the country's outbreak, caused by the Bundibugyo strain, continues to spread and is the largest ever recorded.
A clinical trial of experimental Ebola treatments began in the Democratic Republic of Congo and enrolled its first patient on Thursday. The Ebola outbreak in the country continues to spread and is the largest‑ever recorded outbreak, caused by the Bundibugyo strain of the virus.
World Health Organization Director‑General Tedros Adhanom Ghebreyesus announced the trial and the enrollment of the first patient, according to AP News. The trial will evaluate Mapp Biopharmaceutical’s experimental MBP134 antibody and Gilead’s antiviral drug remdesivir, as reported by The Hindu.
More than 1,400 people have been diagnosed with Ebola and 438 have died, AP News reported. It has been over 50 days since the outbreak was declared in the Democratic Republic of Congo and Uganda, according to GDELT. Residents at the epicenter of the outbreak are pinning their hopes on the experimental treatments, WTAE reported.
This account was written only from facts that survived Augur's
corroboration pass — 4 corroborated across opposed news blocs,
0 contested (attributed to both sides), 5
single-source (attributed). Nothing was added; no significance was inferred.
Model Qwen3-Next-80B-A3B-Instruct.
See the evidence & the verbatim quotes →